Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

05/14/2021 | 05:01pm EDT

Actinium Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 622,000. Operating loss was USD 5.372 million. Net loss was USD 5.320 million.


ę S&P Capital IQ 2021
All news about ACTINIUM PHARMACEUTICALS, INC.
09/16ACTINIUM PHARMACEUTICALS : Completes Enrollment in the Pivotal Phase 3 SIERRA Tr..
AQ
09/15ACTINIUM PHARMACEUTICALS : Completes Enrollment in Phase 3 Trial of Iomab-B to T..
MT
09/15Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SI..
CI
08/03ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price..
MT
07/30ACTINIUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
07/30Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarte..
CI
06/29ACTINIUM PHARMACEUTICALS : Announces Inclusion in Russell Microcap Index
AQ
06/17ACTINIUM PHARMACEUTICALS : Awarded Patents in Europe, Japan for Antibody Radiati..
MT
06/15Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Tria..
CI
06/04ACTINIUM PHARMACEUTICALS : Announces Several Presentations from the Phase 3 SIER..
AQ
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,02 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,85x
Yield 2021 -
Capitalization 167 M 167 M -
Capi. / Sales 2021 164x
Capi. / Sales 2022 10,9x
Nbr of Employees 32
Free-Float 98,5%
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,40 $
Average target price 30,00 $
Spread / Average Target 305%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Mark S. Berger Chief Medical Officer
Dale L. Ludwig Chief Scientific & Technology Officer
Avinash Desai Executive VP-Clinical Development & Operations
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.0.38%167
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850